Senti Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Senti Biosciences, Inc., the gene circuit company focused on outsmarting complex diseases with intelligent medicines, will participate in the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
Tim Lu, CEO and Co-Founder of Senti Biosciences, will present a corporate overview on Wednesday, January 15.
Date: Wednesday, January 15, 2020
Time: 11:00 a.m. PT
Location: Westin St. Francis Hotel, Elizabethan D
About Senti Biosciences
Senti Biosciences is a next-generation therapeutics company that is developing gene circuits and programming cells for tremendous therapeutic value. Our mission is to outsmart complex diseases with more intelligent medicines that will transform people’s lives. By programming cells to respond, adapt and make decisions, we are creating smarter therapies with computer-like logic, enhanced functionality and greater therapeutic control.
In addition, Senti’s gene circuit platform enables next-generation gene therapies with programmable specificity and high activity in defined cell types, as well as gene therapies that can be titrated up or down in a rheostat fashion with FDA-approved small molecule drugs.
Senti Biosciences is based in South San Francisco and was founded in 2016 by Drs. Tim Lu, Philip Lee, Jim Collins and Wilson Wong. Senti is proud to count NEA, 8VC, Amgen Ventures, Lux Capital, Menlo Ventures, Pear Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital among its investors. For more information on Senti Biosciences, please visit https://www.sentibio.com/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005221/en/
CFO and CBO
Source: Senti Biosciences, Inc.
View this news release online at: